封面
市场调查报告书
商品编码
1441148

双特异性抗体的全球市场:药物销售、专利、价格和临床试验见解 (2029)

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029

出版日期: | 出版商: KuicK Research | 英文 1200 Pages | 商品交期: 最快1-2个工作天内

价格

双特异性抗体是一种令人兴奋的新治疗方法,在过去十年中势头强劲。 这些精心设计的分子提供了独特的作用机制,可利用免疫系统精确靶向恶性和其他患病细胞和组织,从而提供一种有针对性的方法,最大限度地降低副作用的风险。 过去三年,双特异性抗体市场的研发和商业活动迅速升温,预计未来几年该市场将快速成长。

双特异性抗体是设计用于同时结合两种不同抗原(通常在不同细胞类型上)的蛋白质。 其双重标靶能力提供了多种利用免疫系统对抗疾病的方法。 对抗癌症的常见方法是引导 T 细胞和自然杀手细胞攻击恶性细胞。 它还可以交联免疫细胞和肿瘤细胞以增强免疫反应。 此外,它还可以阻断两种不同的讯号路径并将免疫细胞招募到肿瘤微环境中。

对于癌症以外的适应症,双特异性抗体可以双重靶向不同的疾病介质或细胞类型。 这提供了中和或消除与发炎、自体免疫和其他疾病有关的致病蛋白、细胞因子和细胞的机会。 然而,根据适应症,双特异性抗体的作用机转可能会有所不同。

与传统的单株抗体相比,双特异性抗体的多功能性具有多种优势,包括更高的特异性、效力和同时靶向多个途径的灵活性。Masu。 这在癌症治疗中具有特殊的意义,其中单株抗体被大量用于抑制各种与癌症相关的途径。 透过将免疫细胞引导至肿瘤,双特异性抗体可以克服肿瘤的免疫逃脱机制,与传统化疗相比,有可能提高疗效并降低毒性。

美国FDA于2014年批准了Blinatumomab(商品名Blincyto),标誌着双特异性抗体治疗復发或难治性B细胞前体急性淋巴细胞白血病领域的一个重要里程碑,从根本上改变了这一法律。 继这一成功之后,几种新的双特异性抗体正在临床开发中,涵盖多种疾病,重点是癌症。 然而,除了癌症之外,还有越来越多的双特异性候选抗体旨在解决病毒和细菌感染以及自体免疫疾病等新兴适应症。 这种多样化凸显了此类药物治疗应用范围的不断扩大。

双特异性抗体已取得足够的临床成功,足以验证其作为主要新药类别的潜力。 它们利用多种疾病途径的独特能力开闢了单株抗体以外的新治疗可能性。 虽然肿瘤学处于领先地位,但向其他疾病领域的扩张也在加速。 分子设计和工程的持续创新使双特异性抗体成为一种令人兴奋的多功能方法,可以改变各种未满足的医疗需求的治疗方法,并且正在越来越多地探索。

本报告调查了全球双特异性抗体市场,并提供了市场概况,包括药物趋势、临床试验趋势、区域趋势以及进入市场的公司竞争格局。

目录

第1章双特异性抗体简介

第2章双特异性抗体的组合策略

  • 化疗
  • 标靶治疗
  • 免疫治疗
  • 放射治疗

第 3 章:深入瞭解商业核准的双特异性抗体

第 4 章双特异性抗体的独特平台

第5章全球与区域双特异性抗体市场展望

  • 年度与季度销售洞察(2019-2023 年)
  • 核准的双特异性抗体报销政策
  • 全球双特异性抗体市场预测:2029 年

第 6 章全球双特异性抗体市场趋势(按地区)

  • 美国
  • 欧洲
  • 中国
  • 英国
  • 日本
  • 韩国
  • 澳大利亚
  • 加拿大
  • 拉丁美洲

第7章全球双特异性抗体的调查与市场趋势(依适应症)

  • 淋巴瘤
  • 多发性骨髓瘤
  • 白血病
  • 肺癌
  • 黑色素瘤
  • 血液疾病
  • 胃肠癌
  • 其他癌症
  • 自体免疫疾病与发炎性疾病
  • 微生物病
  • 眼部疾病

第8章全球双特异性抗体临床试验概述

  • 爱别
  • 依国家/地区
  • 按公司
  • 依指示
  • 依优先权
  • 患者部分

第 9 章 Blincyto - 临床、专利、定价与销售见解

第 10 章 Hemlibra - 临床、专利、定价与销售见解

第 11 章 Rybrevant - 临床、专利和定价见解

第 12 章 Kimmtrak - 临床、专利、定价与销售见解

第 13 章 Vabysmo - 临床、专利、定价与销售见解

第 14 章 Lunumio - 临床、专利、定价与销售见解

第 15 章 Cadnilimab - 临床与销售见解

第 16 章 Tecvayli - 临床、专利和定价见解

第 17 章 Columvi-临床、专利、定价与销售见解

第 18 章 Epkinly - 临床、专利、定价与销售见解

第 19 章 Talvey - 临床、专利和定价见解

第 20 章 Elrexfio - 临床、专利和定价见解

第 21 章按公司、适应症和阶段划分的双特异性抗体全球临床试验

  • 调查
  • 临床前
  • 第一阶段
  • 第一/二期
  • 第二阶段
  • 第二/第三阶段
  • 第三阶段
  • 预先註册
  • 已註册

第 22 章:按公司、国家和适应症划分的市售双特异性抗体的临床见解

第23章竞争态势

  • ABL Bio
  • Abzyme Therapeutics
  • Affimed Therapeutics
  • Akeso Biopharma
  • Alligator Bioscience
  • Amgen
  • Antibody Therapeutics
  • APITBIO
  • Aptevo Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • BioAtla
  • Biosion
  • Biotheus
  • BJ Bioscience
  • EpimAb Biotherapeutics
  • FutureGen Biopharmaceutical
  • Genentech
  • Genmab
  • Gensun Biopharma
  • Harbour BioMed
  • IGM Biosciences
  • I-MAB Biopharma
  • ImmuneOnco Biopharma
  • ImmunoPrecise Antibodies
  • Innovent Biologics
  • Invenra
  • Janssen Research & Development
  • Kenjockety Biotechnology
  • LaNova Medicines Limited
  • Light Chain Bioscience
  • Linton Pharm
  • Lyvgen Biopharma
  • MacroGenics
  • Merus
  • NovaRock Biotherapeutics
  • Pfizer
  • Phanes Therapeutics
  • Prestige BioPharma
  • Regeneron Pharmaceuticals
  • Revitope
  • Roche
  • Virtuoso Therapeutics
  • Xencor
  • Y-Biologics
  • Zhejiang Shimai Pharmaceutical
  • Zymeworks

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029 Report Highlights:

  • Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
  • Global Bispecific Antibodies Market Size Yearly & Quarterly Sales (2018 till 2023)
  • Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
  • Global Bispecific Antibodies Market Forecast Till 2029
  • Approved Bispecific Antibodies Yearly & Quarterly Sales (2018 till 2023)
  • Approved Bispecific Antibodies Regional Sales (2018 till 2023)
  • Clinical & Commercial Insight On Approved Bispecific Antibodies: 12 Antibodies
  • Approved Bispecific Antibodies Pricing & Dosage Analysis
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase: > 800 Antibodies
  • FDA & EMA Fast Track Approval, Orphan Designation, Priority Status Insights

Bispecific antibodies represent an exciting new therapeutic approach that has been gaining momentum since the last decade. These meticulously designed molecules offer a unique mechanism of action that harnesses the immune system to target malignant and other diseased cells and tissues with precision, offering a targeted approach that minimizes the risk of adverse effects. In the last three years, the market of bispecific antibodies has experienced a rapid surge in research and development, and commercial activities, setting the market for a speedy growth in the coming years.

Bispecific antibodies are engineered proteins intended to simultaneously bind two different antigens, typically found on distinct cell types. Their dual targeting ability provides multiple ways to exploit the immune systems against diseases. For cancer, common approaches include redirecting T cells or natural killer cells to attack malignant cells. They can also crosslink immune cells with tumor cells to enhance the immune response. Additionally, they can block two different signaling pathways or recruit immune cells to the tumor microenvironment.

For indications apart from cancer, bispecific antibodies enable dual targeting of different disease mediators or cell types. This provides opportunities to neutralize or clear pathogenic proteins, cytokines or cells involved in inflammation, autoimmunity and other diseases. However, depending on the indications, the mechanism by which bispecific antibodies work can change.

The versatility of bispecific antibodies offers several advantages over their predecessors, traditional monoclonal antibodies, including enhanced specificity, potency and flexibility in targeting multiple pathways at the same time. This become especially relevant in cancer treatment, where monoclonal antibodies are utilized heavily to interfere with different cancer-associated pathways. By directly redirecting immune cells to tumors, bispecific antibodies can overcome tumor immune evasion mechanisms, leading to improved efficacy and potentially lower toxicity compared to conventional chemotherapy.

The US FDA approved Blinatumomab (commercially known as Blincyto) in 2014, marking a key milestone in the field of bispecific antibodies and fundamentally changing how relapsed or refractory precursor B-cell acute lymphoblastic leukemia is treated. Following this success, multiple new bispecific antibodies have arisen in clinical development, covering a wide range of medical disorders, with a focus on cancer. Nonetheless, in addition to cancer, there has been an increase in the number of bispecific candidates designed to address emerging indications such as viral and bacterial infections, as well as autoimmune diseases. This diversification highlights the growing range of therapeutic applications for this class of medicines.

Currently, there are over 800 bispecific candidates in active clinical development. Phase 3 trials are underway across a spectrum of solid cancers like triple negative breast cancer, small cell lung cancer, bladder cancer among others, in addition to hematological cancers, including myeloma and leukemia. Further, a few other phase 3 candidates are also being investigated in indications beyond cancer, like hemophilia A and diabetic macular edema, displaying the diversity in indications.

The heightened attention on the development of this novel therapeutic class has been greatly supported by the increasing global value of the bispecific antibodies market. At present, 12 bispecific antibodies have received approvals in different markets around the globe, which together, generated revenue of over US$ 8.5 Billion in the year 2023. This was an increase of over 47% as compared to the total sales of 2022, which was approximately over US$ 5.8 Billion. A bulk of this value comes from the global sales of Hemlibra, a bispecific antibody indicated for the treatment of Hemophilia A, which is the highest selling member of this drug class.

Since bispecific antibodies were introduced in the market, the US has been a major contributor to the overall sales of these drugs. In 2023, the US market alone generated a revenue of US$ 5.6 Billion, with the international market contributing US$ 2.8 Billion to the total sales. This was an increase of 34% compared to the sales recorded in 2022, showing the growing interest of patients and physicians in novel therapeutics, such as bispecific antibodies.

Therefore, bispecific antibodies have demonstrated enough clinical success to validate their potential as a major new drug class. Their unique ability to tap into multiple disease pathways is unlocking new therapeutic possibilities beyond monoclonal antibodies. While oncology has led the way, expansion into other disease areas is accelerating. With continued innovation in molecular designs and engineering, bispecific antibodies represent an exciting versatile approach to transform treatment across a wide range of unmet medical needs, which researchers are slowly progressing to.

Table of Contents

1. Introduction to Bispecific Antibody

  • 1.1. Overview
  • 1.2. Clinical Advancement of Bispecific Antibodies

2. Bispecific Antibodies Combination Strategies

  • 2.1. Chemotherapies
  • 2.2. Targeted Therapies
  • 2.3. Immunotherapies
  • 2.4. Radiotherapy

3. Commercially Approved Bispecific Antibodies Insight

  • 3.1. Company, Indication, Location & MOA
  • 3.2. Bispecific Antibodies Granted FDA & EMA Designations

4. Bispecific Antibodies Proprietary Platforms

5. Global & Regional Bispecific Antibody Market Outlook

  • 5.1. Yearly & Quarterly Sales Insight (2019 to 2023)
  • 5.2. Approved Bispecific Antibodies Reimbursement Policy
  • 5.3. Global Bispecific Antibody Market Forecast 2029

6. Global Bispecific Antibody Market Trends By Region

  • 6.1. US
  • 6.2. Europe
  • 6.3. China
  • 6.4. UK
  • 6.5. Japan
  • 6.6. South Korea
  • 6.7. Australia
  • 6.8. Canada
  • 6.9. Latin America

7. Global Bispecific Antibodies Research & Market Trends by Indications

  • 7.1. Lymphoma
  • 7.2. Multiple Myeloma
  • 7.3. Leukemia
  • 7.4. Lung Cancer
  • 7.5. Melanoma
  • 7.6. Blood Disorders
  • 7.7. Gastrointestinal Cancers
  • 7.8. Other Cancers
  • 7.9. Autoimmune & Inflammatory Diseases
  • 7.10. Microbial Diseases
  • 7.11. Ocular Diseases

8. Global Bispecific Antibodies Clinical Trials Overview

  • 8.1. By Phase
  • 8.2. By Country/Region
  • 8.3. By Company
  • 8.4. By Indication
  • 8.5. By Priority Status
  • 8.6. Patient Segment

9. Blincyto - Clinical, Patent, Pricing & Sales Insight

  • 9.1. Overview & Patent Insight
  • 9.2. Pricing & Dosage Analysis
  • 9.3. Sales Analysis

10. Hemlibra - Clinical, Patent, Pricing & Sales Insight

  • 10.1. Overview
  • 10.2. Pricing & Dosage Insight
  • 10.3. Sales Analysis

11. Rybrevant - Clinical, Patent & Pricing Insight

  • 11.1. Overview
  • 11.2. Pricing & Dosage Insight

12. Kimmtrak - Clinical, Patent, Pricing & Sales Insight

  • 12.1. Overview
  • 12.2. Pricing & Dosage Insight
  • 12.3. Sales Analysis

13. Vabysmo - Clinical, Patent, Pricing & Sales Insight

  • 13.1. Overview
  • 13.2. Pricing & Dosage Insight
  • 13.3. Sales Analysis

14. Lunsumio - Clinical, Patent, Pricing & Sales Insight

  • 14.1. Overview & Patent Insight
  • 14.2. Pricing & Dosage Insight
  • 14.3. Sales Analysis

15. Cadonilimab - Clinical & Sales Insight

16. Tecvayli - Clinical, Patent & Pricing Insight

  • 16.1. Overview & Patent Insight
  • 16.2. Pricing & Dosage Insight

17. Columvi - Clinical, Patent, Pricing & Sales Insight

  • 17.1. Overview & Patent Insight
  • 17.2. Pricing & Dosage Insight
  • 17.3. Sales Analysis

18. Epkinly - Clinical, Patent, Pricing & Sales Insight

  • 18.1. Overview
  • 18.2. Pricing & Dosage Insight
  • 18.3. Sales Analysis

19. Talvey - Clinical, Patent & Pricing Insight

  • 19.1. Overview & Patent Insight
  • 19.2. Pricing & Dosage Insight

20. Elrexfio - Clinical, Patent & Pricing Insight

  • 20.1. Overview
  • 20.2. Pricing & Dosage Insight

21. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

  • 21.1. Research
  • 21.2. Preclinical
  • 21.3. Phase-I
  • 21.4. Phase-I/II
  • 21.5. Phase-II
  • 21.6. Phase-II/III
  • 21.7. Phase-III
  • 21.8. Preregistration
  • 21.9. Registered

22. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

23. Competitive Landscape

  • 23.1. ABL Bio
  • 23.2. Abzyme Therapeutics
  • 23.3. Affimed Therapeutics
  • 23.4. Akeso Biopharma
  • 23.5. Alligator Bioscience
  • 23.6. Amgen
  • 23.7. Antibody Therapeutics
  • 23.8. APITBIO
  • 23.9. Aptevo Therapeutics
  • 23.10. Astellas Pharma
  • 23.11. AstraZeneca
  • 23.12. BioAtla
  • 23.13. Biosion
  • 23.14. Biotheus
  • 23.15. BJ Bioscience
  • 23.16. EpimAb Biotherapeutics
  • 23.17. FutureGen Biopharmaceutical
  • 23.18. Genentech
  • 23.19. Genmab
  • 23.20. Gensun Biopharma
  • 23.21. Harbour BioMed
  • 23.22. IGM Biosciences
  • 23.23. I-MAB Biopharma
  • 23.24. ImmuneOnco Biopharma
  • 23.25. ImmunoPrecise Antibodies
  • 23.26. Innovent Biologics
  • 23.27. Invenra
  • 23.28. Janssen Research & Development
  • 23.29. Kenjockety Biotechnology
  • 23.30. LaNova Medicines Limited
  • 23.31. Light Chain Bioscience
  • 23.32. Linton Pharm
  • 23.33. Lyvgen Biopharma
  • 23.34. MacroGenics
  • 23.35. Merus
  • 23.36. NovaRock Biotherapeutics
  • 23.37. Pfizer
  • 23.38. Phanes Therapeutics
  • 23.39. Prestige BioPharma
  • 23.40. Regeneron Pharmaceuticals
  • 23.41. Revitope
  • 23.42. Roche
  • 23.43. Virtuoso Therapeutics
  • 23.44. Xencor
  • 23.45. Y-Biologics
  • 23.46. Zhejiang Shimai Pharmaceutical
  • 23.47. Zymeworks

List of Figures

  • Figure 1-1: Bispecific Antibodies - Advantages
  • Figure 2-1: Antibody-Chemotherapy Combination - Advantages
  • Figure 2-2: Antibody-Chemotherapy Combination - Impending Challenges
  • Figure 3-1: Blincyto - Mechanism of Action
  • Figure 3-2: Hemlibra - Mechanism of Action
  • Figure 3-3: Rybrevant - Mechanism of Action
  • Figure 3-4: Regulatory Designations - Benefits
  • Figure 4-1: Multiclonics - Distinctive Characteristics
  • Figure 4-2: Biclonics - Format
  • Figure 4-3: ADAPTIR Bispecific Structure
  • Figure 4-4: ADAPTIR-FLEX
  • Figure 4-5: BEAT Platform - Multispecific Antibodies
  • Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
  • Figure 4-7: BiClone format
  • Figure 4-8: BioAtla CABs - Features
  • Figure 4-9: BioAtla CABs - Benefits
  • Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
  • Figure 4-11: IMBiologic Bispecific Antibodies - Mechanism of Action
  • Figure 4-12: Novel HBICE
  • Figure 4-13: HBICE - Mechanism of Action 1
  • Figure 4-14: HBICE - Mechanism of Action 2
  • Figure 4-15: Phanes Therapeutics - PACbody Platform
  • Figure 4-16: Phanes Therapeutics - SPECpair Platform
  • Figure 4-17: Phanes Therapeutics - ATACCbody
  • Figure 4-18: Numab Therapeutics - Technology
  • Figure 4-19: Grabody I Platform - Mechanism of Action
  • Figure 4-20: Grabody I Platform - Mechanism of Action
  • Figure 4-21: 3-Step DuoBody Production Process
  • Figure 4-22: DuoHexaBody Molecules - Schematic
  • Figure 4-23: iTAb - Patented Structure
  • Figure 4-24: iTAb - Mechanism of Action
  • Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
  • Figure 4-26: BiTE - Structure
  • Figure 4-27: BiTE Molecule
  • Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
  • Figure 4-29: ALiCE - Characteristics
  • Figure 4-30: ALiCE - Schematic Diagram & Mechanism of Action
  • Figure 4-31: Abz2 Bispecific Platform
  • Figure 4-32: Abz2 Bispecifics - Benefits
  • Figure 4-33: Neo-X-Prime Bispecific Mechanism
  • Figure 4-34: B-Body Bispecific Antibody - Structre
  • Figure 4-35: xLinkBsAb - Structure
  • Figure 4-36: PrecisionGATE Bispecific Antibody - Structure
  • Figure 5-1: Global - Annual Bispecific Antibody Market (US$ Million), 2019-2023
  • Figure 5-2: Global - Quarterly Bispecific Antibody Market (US$ Million), 2023
  • Figure 5-3: Global - Annual Bispecific Antibodies Market by Drug (US$ Million), 2023
  • Figure 5-4: Global - Bispecific Antibodies Market Shares by Drugs (%), 2023
  • Figure 5-5: Global - Annual Bispecific Antibody Market by Region (US$ Billion), 2023
  • Figure 5-6: Global - Bispecific Antibody Market Shares by Region (%), 2023
  • Figure 5-7: Global - Annual Bispecific Antibodies Sales by Drugs (US$ Million), 2022
  • Figure 5-8: Global - Bispecific Antibodies Market Shares by Drugs (%), 2022
  • Figure 5-9: Global - Bispecific Antibody Market by Region (US$ Million), 2022
  • Figure 5-10: Global - Bispecific Antibody Market Shares by Region (%), 2022
  • Figure 5-11: US - Annual Bispecific Antibody Market Value (US$ Million), 2019-2023
  • Figure 5-12: ROW - Global Bispecific Antibody Market Value (US$ Million), 2019-2023
  • Figure 5-13: US - Quarterly Bispecific Antibodies Market (US$ Million), 2023
  • Figure 5-14: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2023
  • Figure 5-15: Blincyto - Total Treatment Cost & Reimbursement Cost
  • Figure 5-16: Blincyto - In Pocket & Out of Pocket Cost of Treatment
  • Figure 5-17: Hemlibra - Total Treatment Cost & Reimbursement Cost
  • Figure 5-18: Hemlibra - In Pocket & Out of Pocket Cost of Treatment
  • Figure 5-19: Rybrevant - Maximum Coverage by Medicaid (US$), 2023
  • Figure 5-20: Rybrevant - Maximum Coverage by Private Insurance Coverage (US$), 2021
  • Figure 5-21: Vabysmo - Total Treatment Cost & Reimbursement Cost
  • Figure 5-22: Vabysmo - In Pocket & Out of Pocket Cost of Treatment
  • Figure 5-23: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2024 - 2029
  • Figure 6-1: US - Bispecific Antibodies Approval
  • Figure 6-2: Blincyto - US v/s ROW Sales (US$ Million), 2023
  • Figure 6-3: Blincyto - US v/s ROW Shares (%), 2023
  • Figure 6-4: Blincyto - US v/s ROW Sales (US$ Million), 2022
  • Figure 6-5: Blincyto - US v/s ROW Shares (%), 2022
  • Figure 6-6: Hemlibra - US v/s ROW Sales (US$ Million), 2023
  • Figure 6-7: Hemlibra - US v/s ROW Shares (%), 2023
  • Figure 6-8: Hemlibra - US v/s ROW Sales (US$ Million), 2022
  • Figure 6-9: Hemlibra - US v/s ROW Shares (%), 2022
  • Figure 6-10: Global - US v/s ROW in Bispecific Antibodies Market (US$ Million), 2023
  • Figure 6-11: Global - US v/s ROW Shares in Bispecific Antibodies Market (%), 2023
  • Figure 6-12: Global - US v/s ROW in Bispecific Antibodies Market (US$ Million), 2022
  • Figure 6-13: Global - US v/s ROW Shares in Bispecific Antibodies Market (%), 2022
  • Figure 6-14: Blincyto - US Patent Filing & Expiration Year
  • Figure 6-15: Blincyto - EU Patent Expiration
  • Figure 6-16: Vabysmo - Canada Patent Numbers Expiration & Approval Year
  • Figure 6-17: Hemlibra - Canada Patent Numbers Approval & Expiration Year
  • Figure 6-18: Rybrevant - Canada Patent Numbers Approval & Expiration Year
  • Figure 6-19: Kimmtrak - Canada Patent Number Approval & Expiration Year
  • Figure 7-1: Bispecific Antibodies - Advantages
  • Figure 7-2: TG-1801 Phase 1 Study - Initiation & Completion Year
  • Figure 7-3: Bispecific Antibodies - Future Opportunities
  • Figure 7-4: Mim8 Phase 3 (NCT05053139) Study - Initiation & Completion Year
  • Figure 7-5: Mim8 Phase 3 (NCT05878938) Study - Initiation & Completion Year
  • Figure 7-6: NXT007 Phase 1/2 (NCT05987449) Study - Initiation & Completion Year
  • Figure 7-7: HMB-001 Phase 1/2 (NCT06211634) Study - Initiation & Completion Year
  • Figure 7-8: REGN4018 Phase 1/2 (NCT03564340) Study - Initiation & Completion Year
  • Figure 7-9: PRV-3279 Phase 2 (NCT05087628) Study - Initiation & Completion Year
  • Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2023
  • Figure 8-2: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2024 till 2029
  • Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2024 till 2029
  • Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2023 till 2029
  • Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2023 till 2029
  • Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Patient Segment (Numbers), 2023 till 2029
  • Figure 9-1: Blincyto - Approval Year by Region
  • Figure 9-2: Blincyto - Patent Filing & Expiration Year
  • Figure 9-3: Blincyto - Treatment Regimen Cycles (Weeks)
  • Figure 9-4: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
  • Figure 9-5: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL
  • Figure 9-6: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
  • Figure 9-7: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
  • Figure 9-8: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL
  • Figure 9-9: Global - Blincyto Sales (US$ Million), 2019-2023
  • Figure 9-10: Global - Blincyto Sales (US$ Million), Q1 - Q4'2023
  • Figure 9-11: Blincyto - US v/s ROW Sales (US$ Million), 2023
  • Figure 9-12: Global - Blincyto Sales by Region (%), 2023
  • Figure 9-13: US - Blincyto Sales (US$ Million), Q1 - Q4'2023
  • Figure 9-14: ROW - Blincyto Sales (US$ Million), Q1 - Q4'2023
  • Figure 9-15: US - Blincyto Sales ((US$ Million), 2019-2023
  • Figure 9-16: ROW - Blincyto Sales (US$ Million), 2019-2023
  • Figure 10-1: Hemlibra - Approval Years by Region
  • Figure 10-2: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection (US$), February'2024
  • Figure 10-3: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
  • Figure 10-4: Global - Hemlibra Sales (US$ Million), 2019-2023
  • Figure 10-5: US - Hemlibra Sales (US$ Million), 2019-2023
  • Figure 10-6: Europe - Hemlibra Sales (US$ Million), 2019-2023
  • Figure 10-7: Japan - Hemlibra Sales (US$ Million), 2019-2023
  • Figure 10-8: ROW - Hemlibra Sales (US$ Million), 2019-2023
  • Figure 10-9: Global - US v/s ROW Sales (US$ Million), 2023
  • Figure 10-10: Global - Hemlibra Annual Sales by Region (US$ Million), 2023
  • Figure 10-11: Global - Hemlibra Sales by Region (%), 2023
  • Figure 10-12: Global - Hemlibra Sales (US$ Million), Q1 - Q4'2023
  • Figure 10-13: US - Hemlibra Sales (US$ Million), Q1 - Q4'2023
  • Figure 10-14: Europe - Hemlibra Sales (US$ Million), Q1 - Q4'2023
  • Figure 10-15: Japan - Hemlibra Sales (US$ Million), Q1 - Q4'2023
  • Figure 10-16: ROW - Hemlibra Sales (US$/ US$ Million), Q1 - Q4'2023
  • Figure 11-1: Rybrevant - Price per Unit & Supply of Intravenous Solution (US$), February'2024
  • Figure 11-2: Rybrevant - Recommended Dose Per Cycle by Body Weight (mg)
  • Figure 11-3: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
  • Figure 11-4: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
  • Figure 12-1: Kimmtrak - Approval Year by Region
  • Figure 12-2: Kimmtrak - Cost Per Unit & Per Vial (US$), February'2024
  • Figure 12-3: Global - Annual Kimmtrak Sales (US$ Million), 2021-2023
  • Figure 12-4: Global - Quarterly Kimmtrak Sales (US$ Million), 2023
  • Figure 12-5: Kimmtrak - Sales by Region (US$ Million), 2023
  • Figure 12-6: Kimmtrak - US v/s ROW Market Shares (US$ Million), 2023
  • Figure 12-7: Kimmtrak - US v/s ROW Market Shares (%), 2023
  • Figure 12-8: US - Quarterly Kimmtrak Sales (US$ Million), 2023
  • Figure 12-9: EU - Quarterly Kimmtrak Sales (US$ Million), 2023
  • Figure 12-10 ROW - Quarterly Kimmtrak Sales (US$ Million), 2023
  • Figure 13-1: Vabysmo - Approval Year by Region
  • Figure 13-2: Vabysmo - Price per Unit & Supply of Intravitreal Solution (US$), February'2024
  • Figure 13-3: Global - Vabysmo Sales (US$ Million), 2022-2023
  • Figure 13-4: Global - Vabysmo US v/s ROW Sales (US$ Million), 2023
  • Figure 13-5: Global - Vabysmo Annual Sales by Region (US$ Million), 2023
  • Figure 13-6: Global - Vabysmo Annual Sales by Region (%), 2023
  • Figure 13-7: US - Vabysmo Sales (US$ Million), 2022-2023
  • Figure 13-8: Europe - Vabysmo Sales (US$ Million), 2022-2023
  • Figure 13-9: Japan - Vabysmo Sales (US$ Million), 2022-2023
  • Figure 13-10: ROW - Vabysmo Sales (US$ Million), 2022-2023
  • Figure 13-11: Global - Vabysmo Sales (US$ Million), Q1 - Q4'2023
  • Figure 13-12: US - Vabysmo Sales (US$ Million), Q1 - Q4'2023
  • Figure 13-13: Europe - Vabysmo Sales (US$ Million), Q1 - Q4'2023
  • Figure 13-14: Japan - Vabysmo Sales (US$ Million), Q1 - Q4'2023
  • Figure 13-15: ROW - Vabysmo Sales (US$ Million), Q1 - Q4'2023
  • Figure 14-1: Lunsumio - Approval Years by Region
  • Figure 14-2: US - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), February'2024
  • Figure 14-3: EU - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), February'2024
  • Figure 14-4: Global - Lunsumio Sales (US$ Million), 2022-2023
  • Figure 14-5: US - Lunsumio Sales (US$ Million), 2022-2023
  • Figure 14-6: Europe - Lunsumio Sales (US$ Million), 2022-2023
  • Figure 14-7: Global - Lunsumio Annual Sales by Region (US$ Million), 2023
  • Figure 14-8: Global - Lunsumio Annual Sales by Region (%), 2023
  • Figure 14-9:- Global - Lunsumio Sales (US$ Million), Q1 - Q4'2023
  • Figure 14-10: US - Lunsumio Sales (US$ Million), Q1 - Q4'2023
  • Figure 14-11: Europe - Lunsumio Sales (US$ Million), Q1 - Q4'2023
  • Figure 15-1: Annual - Cadonilimab Sales (US$ Million), H2'2022 & H1'2023
  • Figure 16-1: Tecvayli - Approval Years by Region
  • Figure 16-2: Tecvayli - Patent Acceptance & Expiration Years
  • Figure 16-3: US - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), February'2024
  • Figure 16-4: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), February'2024
  • Figure 17-1: Columvi - Approval Year by Region
  • Figure 17-2: US - Price per Unit & Supply of Columvi Intravenous Solution (US$), February'2024
  • Figure 17-3: EU - Price per Unit & Supply of Columvi Intravenous Solution (US$), February'2024
  • Figure 17-4: Global - Columvi Sales by Region (US$ Million), 2023
  • Figure 17-5: Global - Columvi Sales (US$ Million), Q1 - Q4'2023
  • Figure 17-6: US - Columvi Sales (US$ Million), Q1 - Q4'2023
  • Figure 17-7: Europe - Columvi Sales (US$ Million), Q1 - Q4'2023
  • Figure 18-1: Epkinly - Approval Year by Region
  • Figure 18-2: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), February'2024
  • Figure 18-3: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), February'2024
  • Figure 18-4: Global - Epkinly Sales (US$ Million), 2023
  • Figure 18-5: Global - Epkinly Sales (US$ Million), Q1 - Q4'2023
  • Figure 19-1: Talvey - Approval Year by Region
  • Figure 19-2: Talquetamab - FDA & EMA Designation Year
  • Figure 19-3: Talvey - Patent Acceptance & Expiration Year
  • Figure 19-4: US - Price per Unit & Supply of Talvey Intravenous Solution (US$), February'2024
  • Figure 19-5: EU - Price per Unit & Supply of Talvey Intravenous Solution (US$), February'2024
  • Figure 20-1: Elrexfio - Approval Years by Region
  • Figure 20-2: Elranatamab - FDA & EMA Designation Years
  • Figure 20-3: US - Price per Unit & Supply of Elrexfio Subcutaneous Solution (US$), February'2024

List of Tables

  • Table 2-1: Bispecific Antibody & Chemotherapy Combinations in Clinical Trials
  • Table 2-2: Bispecific Antibody & Targeted Therapy Combinations in Clinical Trials
  • Table 2-3: Bispecific Antibody & Immunotherapy Combinations in Clinical Trials
  • Table 2-4: Bispecific Antibody & Radiotherapy Combinations in Clinical Trials
  • Table 3-1: Approved Bispecific Antibodies
  • Table 3-2: US - Bispecific Antibodies with Regulatory Designations
  • Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
  • Table 3-4: EU - Bispecific Antibodies with Regulatory Designations
  • Table 5-1: Epkinly - Billing Unit Application for Doses
  • Table 5-2: Talvey - Coverage Summary
  • Table 5-3: Talvey - Coding Summary
  • Table 5-4: Elrexfio - HCPCS Codes
  • Table 5-5: Elrexfio - HCPCS modifiers
  • Table 6-1: US - FDA IND Applications Accepted, February'2024
  • Table 6-2: EU - Bispecific Antibodies in Late Stage Clinical Trials
  • Table 6-3: Bispecific Antibodies in Clinical Trials in Latin America
  • Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
  • Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
  • Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
  • Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
  • Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
  • Table 7-6: Digestive System Cancers - Bispecific Antibodies in Clinical Trials
  • Table 7-7: Breast Cancer - Bispecific Antibodies in Clinical Trials
  • Table 7-8: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
  • Table 7-9: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
  • Table 9-1: Blincyto - Active Patents
  • Table 9-2: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
  • Table 9-3: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
  • Table 9-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
  • Table 11-1: Rybrevant - Premedication
  • Table 11-2: Rybrevant - Dose Reductions for Adverse Reactions
  • Table 11-3: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
  • Table 12-1: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma
  • Table 12-2: Kimmtrak - Dose Modifications for Adverse Reactions
  • Table 14-1: Lunsumio - Recommended Treatment Cycles
  • Table 14-2: Lunsumio - Recommended Premedications
  • Table 14-3: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
  • Table 16-1: Tecvayli - Dosing Schedule
  • Table 16-2: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
  • Table 17-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)
  • Table 17-2: Columvi - Premedications to be Administered
  • Table 17-3: Columvi - Recommendations for Management of Cytokine Release Syndrome
  • Table 17-4: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
  • Table 17-5: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 18-1: Epkinly - Dosage Schedule
  • Table 18-2: Epkinly - Recommendations for Management of Cytokine Release Syndrome
  • Table 18-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 18-4: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 19-1: Talvey - Weekly Dosing Schedule
  • Table 19-2: Talvey - Biweekly Dosing Schedule
  • Table 19-3: Talvey - Recommendations for Management of CRS
  • Table 19-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 19-5: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
  • Table 19-6: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 20-1: Elrexfio - Dosing Schedule
  • Table 20-2: Elrexfio - Recommendations for Management of CRS
  • Table 20-3: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions